Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report 2026
Download Free Sample Buy Now
Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Global Report 2026 Market Report Infographic Image

Published : April 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report 2026

Global Outlook – By Disorder (Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies), By Therapy (Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy), By End-User (Hospitals, Specialty Clinics, Ambulatory Surgery Centers) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

• Nucleic Acid And Gene Therapies In Neuromuscular Disorders market size has reached to $7.5 billion in 2025

• Expected to grow to $11.76 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%

• Growth Driver: Rising Prevalence Of Genetic Disorders Fuels Growth In The Market

• Market Trend: Advancements In Gene Therapy For Neuromuscular Disorders

• North America was the largest region in 2025.

What Is Covered Under Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

Nucleic acid and gene therapies in neuromuscular disorders refer to innovative treatments that aim to correct or compensate for the genetic mutations underlying these diseases. Neuromuscular disorders (NMDs) are conditions that affect the muscles and nerves, often due to inherited genetic mutations. These therapies involve the use of nucleic acids or genetic material to repair, replace, or modulate gene expression, thereby addressing the root cause of the disorder.

The main disorders in nucleic acid and gene therapies in neuromuscular disorders are motor neuron diseases, neuropathies, neuromuscular junction disorders, and myopathies including muscular dystrophies. Motor neuron diseases refer to a group of progressive neurological disorders that affect motor neurons, leading to muscle weakness, atrophy, and loss of voluntary movement control. The therapies include adeno-associated viruses gene therapy, postnatal gene therapy, and spinal muscular atrophy. The various applications include hospitals, specialty clinics, and ambulatory surgery centers.

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Global Report 2026 Market Report bar graph

What Is The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size and Share 2026?

The nucleic acid and gene therapies in neuromuscular disorders market size has grown strongly in recent years. It will grow from $7.5 billion in 2025 to $8.22 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to limited therapeutic options for nmds, low awareness of gene therapies, high cost of gene therapy development, lack of specialized treatment centers, slow regulatory approvals.

What Is The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Growth Forecast?

The nucleic acid and gene therapies in neuromuscular disorders market size is expected to see strong growth in the next few years. It will grow to $11.76 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to advancements in adeno-associated virus and postnatal gene therapies, increasing r&d investments in nmds, growing number of hospitals and specialty clinics offering gene therapies, rising prevalence of neuromuscular disorders, increasing patient awareness and advocacy initiatives. Major trends in the forecast period include rising adoption of gene therapy techniques, increasing development of nucleic acid therapeutics, growing focus on rare neuromuscular disorders, rising investment in personalized medicine approaches, increasing integration of advanced diagnostic and monitoring tools.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segmentation

1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies

2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy

3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgery Centers

Subsegments:

1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)

2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies

3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)

4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)

What Is The Driver Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

The increasing prevalence of genetic disorders is expected to propel the growth of the nucleic acid and gene therapies in neuromuscular disorders market going forward. Genetic disorders are diseases caused by abnormalities in an individual's DNA, either inherited or resulting from mutations. The increase in genetic disorders is due to factors such as genetic mutations, environmental influences, lifestyle changes, and improved diagnostic capabilities. Nucleic acid and gene therapies help genetic disorders by correcting or replacing defective genes in neuromuscular conditions to restore normal function. For instance, in May 2024, according to Cure SMA, a US-based non-profit organization, In the United States, approximately 9,000 to 9,500 individuals are currently living with Spinal Muscular Atrophy (SMA). Among the total population, 37% have Type 2 SMA. The condition has an estimated incidence rate of 1 in 15,000 births. Therefore, the increasing prevalence of genetic disorders is driving the growth of the nucleic acid and gene therapies in neuromuscular disorders industry.

Key Players In The Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd.

Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Trends and Insights

Major companies are operating in the nucleic acid and gene therapies in neuromuscular disorders market, focusing on developing innovative therapies such as gene therapy to address the root causes of genetic neuromuscular conditions through targeted gene correction or replacement. Gene therapy refers to the treatment of diseases by introducing, altering, or repairing genetic material within a patient's cells to correct or replace defective genes. For instance, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration for Elevidys, the first gene therapy for Duchenne Muscular Dystrophy, specifically for ambulatory pediatric patients aged 4 to 5 years. The therapy is administered as a single intravenous infusion, simplifying the treatment process compared to other therapies that may require ongoing infusions. ELEVIDYS delivers a gene that codes for a shortened form of dystrophin known as micro-dystrophin, which is essential for muscle function. This innovative approach addresses the underlying genetic defect by enabling muscle cells to produce a functional version of the dystrophin protein, thereby potentially halting or reversing disease progression.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

In November 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired Kate Therapeutics Inc. for $1.1 billion. With this acquisition, Novartis aims to enhance its gene therapy capabilities for inherited neuromuscular diseases by integrating AAV-based gene therapy platform DELIVER and preclinical candidates for Duchenne muscular dystrophy, facioscapulohumeral dystrophy and myotonic dystrophy type 1 into its portfolio. Kate Therapeutics Inc. is a US-based biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for genetically defined muscle and heart diseases.

Regional Outlook

North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

The nucleic acid and gene therapies in neuromuscular disorders market consist of revenue earned by entities by providing services such as genetic diagnostics, personalized therapeutics, and gene delivery. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid and gene therapies in neuromuscular disorders market also include sales of oligonucleotides, gene therapy vectors, and diagnostic kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report 2026?

The nucleic acid and gene therapies in neuromuscular disorders market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid and gene therapies in neuromuscular disorders industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $8.22 billion
Revenue Forecast In 2035 $11.76 billion
Growth Rate CAGR of 9.7% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Disorder, Therapy, End-User
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd.
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.1.2 Biotechnology, Genomics & Precision Medicine

4.1.3 Artificial Intelligence & Autonomous Intelligence

4.1.4 Digitalization, Cloud, Big Data & Cybersecurity

4.1.5 Industry 4.0 & Intelligent Manufacturing

4.2. Major Trends

4.2.1 Rising Adoption Of Gene Therapy Techniques

4.2.2 Increasing Development Of Nucleic Acid Therapeutics

4.2.3 Growing Focus On Rare Neuromuscular Disorders

4.2.4 Rising Investment In Personalized Medicine Approaches

4.2.5 Increasing Integration Of Advanced Diagnostic And Monitoring Tools

5. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Ambulatory Surgery Centers

5.4 Research Institutes

5.5 Genetic Counseling Centers

6. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size, Comparisons And Growth Rate Analysis

7.3. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segmentation

9.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies

9.2. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy

9.3. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Specialty Clinics, Ambulatory Surgery Centers

9.4. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Motor Neuron Diseases, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)

9.5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuropathies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies

9.6. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuromuscular Junction Disorders, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)

9.7. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Myopathies Including Muscular Dystrophies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)

10. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Regional And Country Analysis

10.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

11.1. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

12.1. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

13.1. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

14.1. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

15.1. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

16.1. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

17.1. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

18.1. Taiwan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

19.1. South East Asia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

20.1. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

21.1. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

22.1. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

23.1. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

24.1. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

25.1. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

26.1. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

27.1. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

28.1. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

29.1. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

30.1. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

31.1. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

32.1. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

33.1. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

34.1. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Segmentation By Therapy, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Regulatory and Investment Landscape

36. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Landscape And Company Profiles

36.1. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Company Profiles

36.3.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis

36.3.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Biogen Inc Overview, Products and Services, Strategy and Financial Analysis

37. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Other Major And Innovative Companies

BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease

38. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market

40. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market High Potential Countries, Segments and Strategies

40.1 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2030 - Countries Offering Most New Opportunities

40.2 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2030 - Segments Offering Most New Opportunities

40.3 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Overview Of Key Products - Product Examples
  • Table 2: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Supply Chain Analysis
  • Table 4: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Major Raw Material Providers
  • Table 5: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Major Resource Providers
  • Table 6: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Major Manufacturers (Suppliers)
  • Table 7: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Major Distributors And Channel Partners
  • Table 8: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Key Technologies & Future Trends
  • Table 9: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Major Trends
  • Table 10: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Major End Users
  • Table 11: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market - TAM, US$ Billion, 2025
  • Table 15: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Motor Neuron Diseases, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuropathies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuromuscular Junction Disorders, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Myopathies Including Muscular Dystrophies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Asia-Pacific, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: China, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: India, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: Japan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Australia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Indonesia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: South Korea, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: Taiwan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: South East Asia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: Western Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: UK, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: Germany, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: France, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: Italy, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Spain, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Eastern Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Russia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: North America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: USA, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: Canada, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: South America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: Brazil, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Middle East, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Africa, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 97: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market - Company Scoring Matrix
  • Table 98: Pfizer Inc Financial Performance
  • Table 99: F. Hoffmann-La Roche Ltd Financial Performance
  • Table 100: Sanofi S.A Financial Performance
  • Table 101: Novartis AG Financial Performance
  • Table 102: Biogen Inc Financial Performance
  • Table 103: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Competitive Benchmarking (In USD Billions)
  • Table 104: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Competitive Dashboard
  • Table 105: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 106: Global, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size Gain ($ Billion), Segmentation By Disorder, 2025 – 2030
  • Table 107: Global, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size Gain ($ Billion), Segmentation By Therapy, 2025 – 2030
  • Table 108: Global, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size Gain ($ Billion), Segmentation By End-User, 2025 – 2030

List Of Figures

    Figure 1: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Supply Chain Analysis
  • Figure 4: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Major Raw Material Providers
  • Figure 5: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Major Resource Providers
  • Figure 6: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Major Distributors And Channel Partners
  • Figure 8: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Key Technologies & Future Trends
  • Figure 9: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Major Trends
  • Figure 10: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Major End Users
  • Figure 11: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market - TAM, US$ Billion, 2025
  • Figure 15: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Motor Neuron Diseases, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuropathies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuromuscular Junction Disorders, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Myopathies Including Muscular Dystrophies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Asia-Pacific, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: China, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: India, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: Japan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Australia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Indonesia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: South Korea, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: Taiwan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: South East Asia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: Western Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: UK, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: Germany, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: France, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: Italy, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Spain, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Eastern Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Russia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: North America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: USA, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: Canada, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: South America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: Brazil, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Middle East, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Africa, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 97: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market - Company Scoring Matrix
  • Figure 98: Pfizer Inc Financial Performance
  • Figure 99: F. Hoffmann-La Roche Ltd Financial Performance
  • Figure 100: Sanofi S.A Financial Performance
  • Figure 101: Novartis AG Financial Performance
  • Figure 102: Biogen Inc Financial Performance
  • Figure 103: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Competitive Benchmarking (In USD Billions)
  • Figure 104: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Competitive Dashboard
  • Figure 105: Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 106: Global, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size Gain ($ Billion), Segmentation By Disorder, 2025 – 2030
  • Figure 107: Global, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size Gain ($ Billion), Segmentation By Therapy, 2025 – 2030
  • Figure 108: Global, Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size Gain ($ Billion), Segmentation By End-User, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

Read More About Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Read More About Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Read More About CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

Read More About Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Read More About Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Nucleic Acid Based Gene Therapy Market Report 2026 - Global Outlook – By Technology (Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologie...

Gene Therapy Market Report 2026 - Global Outlook – By Gene Therapy Type (Germline Therapy, Somatic Cell Therapy), By Vector (Viral Vector, Non-Viral Vector), By Application (Oncology, Orphan Disease, Knee Osteoarthritis,...

Oligonucleotide Therapy Market Report 2026 - Global Outlook – By Type (Antisense Oligonucleotide, Aptamer, Other Types), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases...

Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report 2026 - Global Outlook – By Type (RNA Interference (RNAi), RNA Antisense), By Technology (Enabling Technology, Enabled Technology), By Therapeutic Area (Oncology,...

mRNA Therapeutics Market Report 2026 - Global Outlook – By Product (Vaccines, Drugs), By Application (Infectious Diseases, Oncology, Rare Genetic Diseases, Respiratory Diseases, Other Applications), By End Use (Hospitals...

Neurological Disorder Drugs Market Report 2026 - Global Outlook – By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs C...

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report 2026 - Global Outlook – By Type (Small Molecules, Biologics), By Distribution Channel (Offline, Online), By Application (Hospitals, Clinics, Home Care) – Marke...

Duchenne Muscular Dystrophy Market Report 2026 - Global Outlook – By Therapy (Mutation Suppression, Exon Skipping Approach), By Therapeutic Class (Molecular Based Therapies, Steroid Therapy), By Route Of Administration (...

Frequently Asked Questions

The Nucleic Acid And Gene Therapies In Neuromuscular Disorders market was valued at $7.5 billion in 2025, increased to $8.22 billion in 2026, and is projected to reach $11.76 billion by 2030.

The global Nucleic Acid And Gene Therapies In Neuromuscular Disorders market is expected to grow at a CAGR of 9.4% from 2026 to 2035 to reach $11.76 billion by 2035.

Some Key Players in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market Include, Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd. .

Major trend in this market includes: Advancements In Gene Therapy For Neuromuscular Disorders. For further insights on this market. request a sample here

North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2025. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us